APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial

  • Treatment was safe and well tolerated and no drug-related severe adverse events were observed
  • Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed
  • Biomarker development supports APN01’s mode of action against SARS-CoV-2
  • Investigators and experts recommend further development of APN01 in COVID-19

Press release (EN) | Presseaussendung (DE)